PDRN for Keloid Scars: How It Works, Evidence & Treatment Options

How PDRN Targets Keloid Scars

PDRN addresses keloid scars through a sophisticated modulation of the wound healing cascade that differentiates it from conventional anti-scarring treatments. The primary mechanism involves adenosine A2A receptor activation, which triggers a potent anti-inflammatory response that specifically downregulates the cytokines most implicated in keloid pathogenesis: TGF-beta (the master regulator of fibrosis), TNF-alpha, IL-6, and IL-13. By suppressing these pro-fibrotic signals, PDRN reduces the pathological overstimulation of keloid fibroblasts that drives excessive collagen deposition. Critically, this anti-inflammatory action is selective rather than broadly immunosuppressive — PDRN does not cause the tissue atrophy, hypopigmentation, or systemic effects associated with corticosteroid therapy. PDRN simultaneously promotes healthy extracellular matrix remodeling by stimulating normal fibroblast function and balanced collagen turnover. This helps shift the ratio of collagen types within keloid tissue toward a more normal composition and encourages the cross-linking and organization of collagen fibers into parallel arrays rather than the chaotic whorls characteristic of keloid tissue. PDRN also enhances microvascular remodeling through regulated angiogenesis, improving blood flow patterns within keloid tissue that are often abnormal and contribute to the hypoxic microenvironment that perpetuates fibrotic signaling. The nucleotide fragments in PDRN provide cellular building blocks that support DNA repair and normal cell cycle regulation in keloid fibroblasts, which often exhibit abnormal proliferative behavior and resistance to apoptosis.

Keloid treatment remains one of the most challenging problems in dermatology because the same wound healing mechanisms that cause keloids are also triggered by most therapeutic interventions. Surgical excision alone has recurrence rates of 50-80%, as the surgical wound itself can trigger new keloid formation. Current standard therapies include intralesional corticosteroid injections (triamcinolone acetonide) to suppress collagen production, silicone sheeting, cryotherapy, radiation therapy, and combination approaches. While corticosteroids remain first-line treatment, they carry risks of skin atrophy, telangiectasia, hypopigmentation, and systemic side effects with repeated use, and many keloids prove refractory to steroid therapy alone.

PDRN (polydeoxyribonucleotide) has emerged as a promising adjunctive therapy for keloid scars due to its unique dual capacity to simultaneously suppress pathological inflammation while promoting healthy tissue remodeling. Unlike corticosteroids that broadly suppress immune function and can cause tissue atrophy, PDRN specifically modulates the inflammatory cascade through adenosine A2A receptor activation, downregulating the pro-inflammatory and pro-fibrotic cytokines (TNF-alpha, IL-6, TGF-beta) that drive keloid growth while preserving normal immune surveillance. This targeted anti-inflammatory action makes PDRN an attractive complement or potential alternative to repeated steroid injections for patients experiencing steroid-related side effects.

The tissue remodeling properties of PDRN are particularly relevant to keloid management. Rather than simply suppressing all collagen production as corticosteroids do, PDRN promotes organized, healthy collagen synthesis while its anti-inflammatory action reduces the chaotic overproduction that characterizes keloid tissue. PDRN supports the shift from a fibrotic, inflammatory tissue state to a more normal reparative state, encouraging the maturation and reorganization of existing scar tissue. When combined with other keloid therapies — particularly after surgical excision, cryotherapy, or laser treatment — PDRN may help prevent recurrence by normalizing the wound healing response in keloid-prone tissue and reducing the inflammatory triggers that initiate keloid regrowth.